Press Release
XBiotech Announces Additions To Its Scientific Advisory Board
Dr.
XBiotech’s SAB Members in Oncology Include:
- Thierry André, M.D. Dr. André is currently Professor of Medical Oncology at the University Pierre et
Marie Curie (UMPC), Paris VI, and Head of theMedical Oncology Department inSt. Antoine Hospital , Assistance Publique Hôpitaux deParis . He is the Founding member and General Secretary of the GERCOR (Multidisciplinary Oncology Research Group ) and leads the colorectal task force of GERCOR and also serves as a Member of the Adjuvant Colon Cancer Endpoints (ACCENT) group. Dr. André’s main research interest is in gastrointestinal malignancies. Dr. André is a member of several scientific organizations including theAmerican Society of Clinical Oncology (ASCO ) and theEuropean Society for Medical Oncology (ESMO), and was chairman of theGI Cancer Board for Research of the French National Institute (INCA). George A. Fisher, Jr. M.D., Ph.D. Dr. Fisher is a medical oncologist and gastrointestinal specialist and is the Colleen Haas Chair atStanford University School of Medicine . Dr. Fisher has been the National Chair of XBiotech’s Phase III study since evaluating the Company’s lead antibody product candidate for the treatment of advanced colorectal cancer. His clinical and research interests are focused on gastrointestinal malignancies, combined modality therapy in gastric, esophageal, pancreas and rectal cancers, immunotherapy, and translational research. He is a member of theStanford Cancer Institute and has held numerous administrative appointments at theStanford University School of Medicine including Director for the Cancer Clinical Trials Office.Andrew Hendifar , M.D. Dr. Hendifar is the Co-Director of Pancreas Oncology and Medical Oncology Lead forGastrointestinal Disease Research at Cedars-Sinai. Dr. Hendifar has been an important Principal Investigator in XBiotech’s Phase III study for colorectal cancer, where he has made important clinical observations in patients. Dr. Hendifar is performing pioneering work in the development of new approaches to treat and evaluate therapies in pancreatic cancer. His work to elucidate the importance of body mass index and biomarkers as prognosticators in cancer is providing new insight on the importance of new measures in disease management and therapeutic strategies. Dr. Hendifar's findings have been published in prestigious journals, including the Lancet, Cancer,Journal of Clinical Oncology , andClinical Cancer Research . Dr. Hendifar has displayed deep subject-matter knowledge in presentations for organizations such as theNational Institutes of Health and theAmerican Society of Clinical Oncology .Alexander Knuth , M.D. Dr. Knuth is a medical oncologist with a long research interest and major contributions to cancer immunology. For years, Dr. Knuth worked closely with Dr.Lloyd Old and theLudwig Institute for Cancer Research , pioneering the characterization of tumor associated antigens and immunotherapies. Dr. Knuth is Professor Emeritus of theUniversity of Zurich where he held the Chair of Internal Medicine/Oncology at theUniversity Hospital (UZH) from 2003 until 2013. At UZH, Dr. Knuth used XBiotech’s candidate therapeutic antibody for colorectal cancer under compassionate protocols. Prior to heading oncology at UZH, Dr. Knuth was Chief Physician of Hematology & Oncology atNorthwest Hospital inFrankfurt, Germany . He has received many awards, including the prestigiousJohann-Georg-Zimmermann Medal . Dr. Knuth is a member of the Cancer Research Institute’s (CRI)Scientific Advisory Council and is a member of CRI’s global clinical investigator network. Dr. Knuth is currently the Medical Director and Chief Executive Officer of theNational Center for Cancer Care and Research (NCCCR) and Chairman of Cancer Services atHamad Medical Corporation inDoha, Qatar .Razelle Kurzrock , M.D. Dr. Kurzrock is a medical oncologist and a renowned expert in precision medicine. She is a thought leader in the use of anti-cytokine therapies for the treatment of cancer and one of the first to recognize the importance of the interleukin-1 pathway in cancer. While at theUniversity of Texas MD Anderson Cancer Center , Dr. Kurzrock built one of the most successful Phase 1 clinical trials programs in the nation, and was the senior author in the pioneering study for the Company’s colorectal cancer study. Dr. Kurzrock currently serves as Senior Deputy Center Director for Clinical Science, Director at theCenter for Personalized Cancer Therapy , Director of the Clinical Trials Office, and a Team Leader for Experimental Therapeutics at theMoores Cancer Center at UC San Diego. Dr. Kurzrock is also Chief of the Hematology & Oncology Division in theUC San Diego School of Medicine .
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
About XBiotech
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our
ContactAshley Otero aotero@xbiotech.com 512-386-2930